Brief: Ideaya Biosciences Inc - Enters Clinical Collaboration Agreement With Astrazeneca On April 8, 2026 - SEC Filing
09/04/2026 11:13
April 9 (Reuters) - IDEAYA Biosciences Inc IDYA.O: IDEAYA BIOSCIENCES INC - ENTERS CLINICAL COLLABORATION AGREEMENT WITH ASTRAZENECA ON APRIL 8, 2026 - SEC FILING IDEAYA BIOSCIENCES INC - AGREEMENT TO EVALUATE IDE849 WITH IMFINZI IN EXTENSIVE-STAGE SMALL CELL LUNG CANCER - SEC FILING IDEAYA BIOSCIENCES INC - CO TO SPONSOR STUDY; ASTRAZENECA TO SUPPLY IMFINZI - SEC FILING IDEAYA BIOSCIENCES INC - ADVANCING GLOBAL PHASE 1 TRIAL FOR IDE849 IN DLL3 UPREGULATED SOLID TUMORS - SEC FILING Further company coverage: IDYA.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on IDEAYA Biosciences
See all newsBrief: Ideaya Biosciences And Servier Announce Data From Three Clinical Trials At Esmo 2026 Supporting The Potential Of Darovasertib To Become A Foundational New Therapy For Patients Across The Treatment Journey Of Uveal Melanoma
Brief: Ideaya Biosciences Announces The Promotion Of Dr. Michael White To President, Research And Development
Brief: Ideaya Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Ideaya Biosciences Inc Reports Results For The Quarter Ended June 30: Earnings Summary
U.S. STOCKS ON THE MOVE-Cleveland-Cliffs, Ciena Corp, Nokia Oyj